A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major

References

• Origa R. β-Thalassemia. Genet Med. 2017;19(6):609–619. doi:10.1038/gim.2016.17327811859
   PubMed Web of Science ®Google Scholar
• Kremastinos DT, Farmakis D, Aessopos A, et al. β-thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circ Hear Fail. 2010;3(3):451–458. doi:10.1161/CIRCHEARTFAILURE.109.913863
   PubMed Web of Science ®Google Scholar
• Hakeem GLA, Mousa SO, Moustafa AN, Mahgoob MH, Hassan EE. Health-related quality of life in pediatric and adolescent patients with transfusion-dependent ß-thalassemia in upper Egypt (single center study). Health Qual Life Outcomes. 2018;16(1):59. doi:10.1186/s12955-018-0893-z29631616
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876–1884. doi:10.1161/CIRCULATIONAHA.106.64879017372174
   PubMed Web of Science ®Google Scholar
• Gujja P, Rosing DR, Tripodi DJ, Shizukuda Y. Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol. 2010;56(13):1001–1012. doi:10.1016/j.jacc.2010.03.08320846597
   PubMed Web of Science ®Google Scholar
• Carpenter J, He T, Kirk P, et al. NIH public access. Circulation. 2012;123(14):1519–1528. doi:10.1161/CIRCULATIONAHA.110.007641.On
   Google Scholar
• Pennell DJ, Porter JB, Piga A, et al. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. Am J Hematol. 2015;90(2):91–96. doi:10.1002/ajh.2387625345697
   PubMed Web of Science ®Google Scholar
• Gillin JC, van Kammen DP, Graves J, Murphy D. Differential effects of D- and L-amphetamine on the sleep of depressed patients. Life Sci. 1975;17(8):1233–1240. doi:10.3324/haematol.2011.049957
   Web of Science ®Google Scholar
• Noetzli LJ, Carson SM, Nord AS, et al. Longitudinal analysis of heart and liver iron in thalassemia major Longitudinal analysis of heart and liver iron in thalassemia major. October. 2008;112(7):2973–2978. doi:10.1182/blood-2008-04-148767
   Web of Science ®Google Scholar
• Aydinok Y, Porter JB, Piga A, et al. Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study. Eur J Haematol. 2015;95(3):244–253. doi:10.1111/ejh.1248725418187
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738–3744. doi:10.1182/blood-2005-07-294816352815
   PubMed Web of Science ®Google Scholar
• Soltanpour MS, Davari K. The correlation of cardiac and hepatic hemosiderosis as measured by T2*MRI technique with ferritin levels and hemochromatosis gene mutations in Iranian patients with beta thalassemia major. Oman Med J. 2018;33(1):48–54. doi:10.5001/omj.2018.0929467999
   PubMedGoogle Scholar
• Pepe A, Positano V, Santarelli MF, et al. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Reson Imaging. 2006;23:662–668. doi:10.1002/jmri.2056616568436
   PubMed Web of Science ®Google Scholar
• Habib G, Bucciarelli-Ducci C, Caforio ALP, et al. Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus document In collaboration with the “Working Group on myocardial and pericardial diseases” of the European Society of Cardiology Endorsed by The Indian Academy of Echocardiography. Eur Heart J Cardiovasc Imaging. 2017;18(10):1090–1121. doi:10.1093/ehjci/jex03428510718
   PubMed Web of Science ®Google Scholar
• He T, Gatehouse PD, Smith GC, Mohiaddin RH, Pennell DJ, Firmin DN. Myocardial T2* measurements in iron overloaded thalassemia. Magn Reson Med. 2008;60(5):1082–1089. doi:10.1002/mrm.21744.Myocardial18956471
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–1193.15477202
   PubMed Web of Science ®Google Scholar
• Davis BA, O’Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood. 2004;104(1):263–269. doi:10.1182/blood-2003-08-284115001468
   PubMed Web of Science ®Google Scholar
• Wijarnpreecha K, Kumfu S, Chattipakorn SC, Chattipakorn N. Cardiomyopathy associated with iron overload: how does iron enter myocytes and what are the implications for pharmacological therapy? Hemoglobin. 2015;39(1):9–17. doi:10.3109/03630269.2014.98786925572185
   PubMed Web of Science ®Google Scholar
• Kumfu S, Chattipakorn S, Chinda K, Fucharoen S, Chattipakorn N. T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice. Eur J Haematol. 2012;88(6):535–548. doi:10.1111/j.1600-0609.2012.01779.x22404220
   PubMed Web of Science ®Google Scholar
• Lopin KV, Gray IP, Obejero-Paz CA, Thevenod F, Jones SW. Fe2+ Block and Permeation of CaV3.1 (1G) T-Type Calcium Channels: candidate Mechanism for Non-Transferrin-Mediated Fe2+ Influx. Mol Pharmacol. 2012;82(6):1194–1204. doi:10.1124/mol.112.08018422973060
   PubMed Web of Science ®Google Scholar
• Oudit GY, Trivieri MG, Khaper N, Liu PP, Backx PH. Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med. 2006;84(5):349–364. doi:10.1007/s00109-005-0029-x16604332
   PubMed Web of Science ®Google Scholar
• Lee YJ, Park HH, Koh SH, Choi NY, Lee KY. Amlodipine besylate and amlodipine camsylate prevent cortical neuronal cell death induced by oxidative stress. J Neurochem. 2011;119(6):1262–1270. doi:10.1111/j.1471-4159.2011.07529.x21988238
   PubMed Web of Science ®Google Scholar
• Rosenkranz AC, Lob H, Breitenbach T, Berkels R, Roesen R. Endothelial antioxidant actions of dihydropyridines and angiotensin converting enzyme inhibitors. Eur J Pharmacol. 2006;529(1–3):55–62. doi:10.1016/j.ejphar.2005.10.04616313901
   PubMed Web of Science ®Google Scholar
• Salehi I, Mohammadi M, Mirzaei F, Soufi FG. Amlodipine attenuates oxidative stress in the heart and blood of high-cholesterol diet rabbits. Cardiovasc J Afr. 2012;23(1):18–22. doi:10.5830/CVJA-2010-09122331246
   PubMed Web of Science ®Google Scholar
• Buck ML, Pharm D. A Monthly Newsletter for Health Care Professionals from the. Schizophrenia. 2008;14(1):6–9. doi:10.13422/j.cnki.syfjx.2012.02.067
   Google Scholar
• Fernandes JL, Loggetto SR, Ver MPA, et al. A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major. Blood. 2016;128(12):1555–1562. doi:10.1182/blood-2016-06-721183.The27412888
   PubMed Web of Science ®Google Scholar
• Shakoor A, Zahoor M, Sadaf A, et al. Effect of l-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: protocol for a randomised, controlled trial. BMJ Open. 2014;4(12). doi:10.1136/bmjopen-2014-005360
   PubMed Web of Science ®Google Scholar
• Eghbali A, Kazemi H, Taherahmadi H, Ghandi Y, Rafiei M, Bagheri B. A randomized, controlled study evaluating effects of amlodipine addition to chelators to reduce iron loading in patients with thalassemia major. Eur J Haematol. 2017;577–581. doi:10.1111/ejh.12977
   Google Scholar
• Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica. 2011;96(1):48–54. doi:10.3324/haematol.2010.03146821071497
   PubMed Web of Science ®Google Scholar
• Ghugre NR, Enriquez CM, Coates TD, Nelson MD Jr, Jr N, Wood JC. Improved R2* measurements in myocardial iron overload. J Magn Reson Imaging 2006;23(1):9–16. doi:10.1002/jmri.20467.Improved
   Google Scholar
• Garbowski MW, Carpenter JP, Smith G, et al. Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. J Cardiovasc Magn Reson. 2014;16(1):1–11. doi:10.1186/1532-429X-16-4024387349
   PubMed Web of Science ®Google Scholar
• Pepe A, Meloni A, Rossi G, et al. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy. J Cardiovasc Magn Reson. 2013;15(1):1–11. doi:10.1186/1532-429X-15-123324167
   PubMed Web of Science ®Google Scholar
• Positano V, Pepe A, Santarelli MF, et al. Standardized T2* map of normal human heart in vivo to correct T2* segmental artefacts. NMR Biomed. 2007;20:578–590. doi:10.1002/nbm.112117205488
   PubMed Web of Science ®Google Scholar
• Ramazzotti A, Pepe A, Positano V, et al. Standardized T2* map of a normal human heart to correct T2* segmental artefacts; myocardial iron overload and fibrosis in thalassemia intermedia versus thalassemia major patients and electrocardiogram changes in thalassemia major patients. Hemoglobin. 2008;32:97–107. doi:10.1080/0363026070187951418274987
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Udelson JE, Arai AE, et al. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the american heart association. Circulation. 2013;128(3):281–308. doi:10.1161/CIR.0b013e31829b2be623775258
   PubMed Web of Science ®Google Scholar
• Wongjaikam S, Kumfu S, Chattipakorn SC, Fucharoen S, Chattipakorn N. Current and future treatment strategies for iron overload cardiomyopathy. Eur J Pharmacol. 2015;765:86–93. doi:10.1016/j.ejphar.2015.08.01726291660
   PubMed Web of Science ®Google Scholar
• Sadaf A, Hasan B, Das JK, Colan S, Alvi N. Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia. Cochrane Database Syst Rev. 2018;2018(7). doi:10.1002/14651858.CD011626.pub2
   Web of Science ®Google Scholar
• Opelz G, Wujciak T. The New England Journal of Medicine Downloaded from nejm.org at ALBERT EINSTEIN COLLEGE OF MEDICINE on November 22, 2011. For personal use only. No other uses without permission. Copyright © 1994 Massachusetts Medical Society. All rights reserved. Nejm. 2011;331(1):5–9. doi:10.1056/NEJM199409293311301
   Web of Science ®Google Scholar
• Guillaume T, Rubinstein DB, Sysman M. The journal of the American Society of Hematology. J Am Soc Hematol. 2016;92(5):1471–1491. doi:10.1007/s00542-013-2002-x
   Web of Science ®Google Scholar
• Eghbali A, Taherahmadi H, Shahbazi M, Bagheri B, Ebrahimi L. Association between serum ferritin level, cardiac and hepatic T2-star {MRI} in patients with major β-thalassemia. Iran J Ped Hematol Oncol. 2014;4(1):17–21.24734159
   PubMedGoogle Scholar
• Triggle DJ. Calcium channel antagonists: clinical uses-Past, present and future. Biochem Pharmacol. 2007;74(1):1–9. doi:10.1016/j.bcp.2007.01.01617276408
   PubMed Web of Science ®Google Scholar
• DeWitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol Rev. 2004;23(4):223–238.15898828
   PubMedGoogle Scholar